Immix Biopharma doses first patient in U.S. AL amyloidosis trial (NASDAQ:IMMX)
2024-07-08
Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201. The company added that the timing of the milestone was in-line with its mid-2024 guidance. It also added that the data from its ex-US clinical trial reported at ASGCT 2024Continue Reading